Targeting vascular endothelial growth factor in renal cell carcinoma.
Renal cancer is the most lethal of all urological malignancies with overall 5-year survival rates of around 60%. The predominant reason for the poor prognosis of this cancer has been the relative lack of effective systemic therapy for advanced metastatic disease. Until recently immunotherapy with in...
Հիմնական հեղինակներ: | Patel, N, Muneer, A, Blick, C, Arya, M, Harris, A |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2009
|
Նմանատիպ նյութեր
-
Vascular endothelial growth factor expression in renal cell carcinoma
: Mohtarrudin, Norhafizah, և այլն
Հրապարակվել է: (2018) -
Renal damage associated with anti-vascular endothelial growth factor treatment
: Pradeep K Panigrahi, և այլն
Հրապարակվել է: (2024-01-01) -
Sirolimus Toxicity and Vascular Endothelial Growth Factor Release From Islet and Renal Cell Lines
: Laugharne, M, և այլն
Հրապարակվել է: (2007) -
Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
: Brown, J, և այլն
Հրապարակվել է: (2024) -
Vascular endothelial growth factor expression in lung cancer.
: O'Byrne, K, և այլն
Հրապարակվել է: (1998)